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Medical evaluation and management of male and female voiding dysfunction: a review
ALANA MURPHY, SETH TEPLITSKY, AKHIL K. DAS, JOON YAU LEONG, ANDREW MARGULES, COSTAS D. LALLAS
Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA

A significant workforce shortage of urologists available to serve the US population has been
projected to occur over the next decade. Accordingly, much of the management of urologic patients
will need to be assumed by other specialties and practitioners. Since primary care physicians are often
first evaluate common urologic complaints, it makes sense that these physicians are in an excellent
position to intervene in the management of these patients when appropriate. One of the most common
complaints in urology is voiding dysfunction. The incidence of voiding dysfunction increases with
age, with conservative estimates showing that over 50% of elderly patients suffer. Despite this high
prevalence and its negative impact on quality of life, however, few seek or receive treatment, as many
do not readily disclose these impactful yet personal symptoms. We sought to summarize the typical
presentation, evaluation, assessment and therapeutic options for both male and female patients
presenting with voiding dysfunction.
Key words: urology, urinary incontinence, referral and consultation, urination disorders,
disease management.

INTRODUCTION

Voiding dysfunction is a term used to describe
the many conditions resulting from impairment
within the lower urinary tract, including the bladder,
prostate (in men), and urethra. This is a widespread
problem that is estimated to affect over half of the
elderly population in this country [1]. It is
estimated that 5% of men between the age of 20-44
and 17% of women over the age of 20 suffer from
voiding dysfunction such as incontinence, which
makes up a large percentage of this dysfunction [2,
3]. However, due to the fear of disclosing these
embarrassing symptoms, this value is often underestimated. Furthermore, voiding dysfunction is
costly, with incontinence alone estimated to cost
$19.5 billion in 2000 [4]. Since that time, the
prevalence of voiding dysfunction has continued to
increase. In addition to this widespread problem,
the physicians who historically have managed these
patients, namely urologists, are suffering from an
impending workforce shortage. There has been a
decreasing supply of urologists relative to population
growth over the last ten years which will only
continue to widen in the future [5]. Given that the
average patient age managed by urologists is one of
the highest among specialties, it is essential that
other clinicians carry a primary role in the treatment
of voiding dysfunction as well. Hence, familiarity
with the signs and symptoms, evaluation and

treatment options, as well as recognition of when a
urology referral is necessary, are critical so that
patients may receive timely and effective treatment.
MALE VOIDING DYSFUNCTION
MALE STRESS URINARY INCONTINENCE (SUI)

Stress urinary incontinence (SUI) is an involuntary loss of urine during physical exertion or
physical activity [6]. Men who have undergone
surgical treatment or radiation therapy for prostatic
conditions, such as an enlarged prostate or cancer,
have an increased risk of developing SUI [7]. Men
who undergo multiple prostatic treatments have a
substantially higher risk of developing SUI when
compared to those who have only undergone a
single treatment modality.
Pathophysiology
SUI occurs when the urethral resistance cannot
overcome the increased intravesical pressure, which
primarily comes from the abdomen. In the male
patient, significant risk factors for SUI include increasing age and prior prostate procedures [8]. SUI
is usually the result of post-surgical or postradiation changes in the lower urinary tract. The
internal sphincter is located at the juncture of the
bladder neck and prostate, and is therefore
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susceptible to damage during endoscopic procedures,
while the external sphincter is made up of the
musculature of the pelvic floor. This disease process
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is thought to be due to injury to the internal urinary
sphincter and a lack of mobility of the external
sphincter [9].

Table 1
This table provides a brief summary of voiding dysfunctions diagnoses, how to identify via history taking,
and when urologic referral is indicated
Condition
Clinical History
Stress Urinary Incontinence (SUI) Urinary incontinence with Valsalva
maneuvers (e.g. coughing, laughing,
sneezing, running)
Sudden compelling desire to void ±
Over Active Bladder (OAB)
urinary frequency

Indication for Urologic Referral
1. Inadequate clinical improvement following pelvic floor
muscle therapy
2. Patient preference for surgical intervention
1. Inadequate clinical improvement follow behavioral
modifications (fluid management and minimization of
bladder irritants) + failure to respond to 1 or 2 OAB
medications
2. Concern for incomplete bladder emptying
3. Patients with neurogenic bladder (e.g. multiple
sclerosis, Parkinson’s disease, spinal cord injury)
4. Patients with gross or microhematuria
Urge Urinary Incontinence (UUI) Urinary incontinence associated with 1. Inadequate clinical improvement following behavioral
urgency (not able to make it to the modifications (fluid management and minimization of
bathroom in time)
bladder irritants) + failure to respond to 1 or 2 OAB
medications
2. Concern for incomplete bladder emptying
3. Patients with neurogenic bladder (e.g. multiple sclerosis,
Parkinson’s disease, spinal cord injury)
4. Patients with gross or microhematuria
Lower Urinary Tract Symptoms Irritative voiding symptoms (urinary 1. Failure to respond to 1 or 2 BPH medications
(LUTS) from Benign Prostatic frequency, urgency, urge incontinence 2. Patient preference for surgical intervention
and nocturia) and obstructive voiding 3. Concern for incomplete bladder emptying or retention
Hyperplasia (BPH)
symptoms (weak urinary flow rate, 4. Renal impairment
straining, urinary retention, overflow 5. Patients with gross or microhematuria
6. Abnormal digital rectal exam or elevated prostate specific
incontinence)
antigen
Overflow Urinary Incontinence and Symptoms of storage, such as nocturia, 1. Upon diagnosis for proper testing and management
urgency, and frequency, or a lack of
Detrusor Underactivity
any urge to void at all which may
cause overflow incontinence
Interstitial Cystitis (IC)/Bladder Increased discomfort (sensations of 1. Inadequate clinical improvement following behavioral
pressure, pain, or spasms of the supra- modifications (heat and cold to area of discomfort,
Hypersensitivity
pubic or urethral regions) with bladder minimization of causative agents)
filling and immediate relief with 2. Inadequate clinical improvement following first line
medications
voiding [47, 48]
3. Patient preference for surgical intervention
Urinary storage symptoms (nocturia, 1. Inadequate clinical improvement following lifestyle
Dysfunctional Voiding (DV)
urgency, fruqency) along with in- modifications
continence throughout the day
2. Patient preference for surgical intervention
Bladder Neck Dysfunction (BND) Hesitancy, pelvic discomfort, fre- 1. Inadequate clinical improvement following first line
quency, urgency, hesitancy and sense medication (alpha-adrenergic antagonists)
of incomplete emptying or impaired
stream

Clinical presentation

Assessment and diagnosis

Men with SUI usually describes leakage of
urine with physical activity or Valsalva maneuvers
such as coughing, laughing or lifting anything
heavy. Often, they wear pads or diapers to conceal
the leakage. SUI generally does not pose a
significant medical issue but has a negative impact
on quality of life and independence, and poses a
financial burden due to the cost of daily pads or
diapers [9].

Obtaining a detailed voiding and leakage
history from the patient is the first step in
identifying SUI in men. Differentiating SUI from
urge urinary incontinence (UUI), overflow urinary
incontinence, or mixed urinary incontinence may
be difficult, but remains critical since treatments
differ. These are usually distinguished by careful
history taking. Occasionally, urodynamic study
and/or cystoscopy from an urologist are necessary
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to confirm the diagnosis. It is critical to uncover the
duration of symptoms and severity, as well as to
assess whether the patient is distressed. Those who
are not troubled by their leakage rarely require
treatment. Severity can be evaluated by the number
of pads or diapers used per day if the patient is
using such, with pad weight further helping
quantify the degree of leakage, as some patients are
more fastidious about changing. When performing
an exam of the abdomen and external genitalia, the
patient’s bladder should be full. Urinary leakage
demonstrated when the patient bears down (Valsalva
maneuver) is pathognomonic for SUI. However,
demonstration of SUI in the office, although
helpful, is not required for nonsurgical or surgical
intervention.
Nonsurgical treatment
Once reversible causes are excluded, nonsurgical options are the first line of therapy for the
management of SUI before surgical intervention.
Lifestyle interventions are the first step, with
recommendations for decreasing caffeine intake,
promotion of weight loss, and encouragement for
smoking cessation [9]. If lifestyle modifications do
not succeed, further treatments include daily pelvic
floor muscle therapy regimens such as Kegel
exercises. As many patients are not able to correctly
perform Kegel exercises, a pelvic floor physical
therapist may be helpful for those patients, aiding
them in identifying the precise muscles required for
training [10]. Overall, Kegel exercises have been
shown to decrease the severity of leakage and
improve quality of life scores for those patients
suffering from SUI [11]. Medical therapies, such as
with antimuscarinic medications, have shown limited
success in treating SUI [12] and are most effective
in patients with mixed incontinence. If a patient has
tried these therapies for at least a year without
improvement, surgical management for SUI can be
considered.
Surgical treatment
Men with SUI impacting their quality of life
can opt for surgical treatment after failing nonsurgical treatment. There are three surgical options
for the management of SUI in men. The least
invasive is a bulking agent injected near the bladder
neck, meant to improve urethral coaptation. Short
term success rates are poor at 43% [13]. The success
of this procedure is dependent on urethral pliability
to accommodate the bulking agent. Another option
is to increase the urethral resistance via a male
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sling. The short-term results have been variable, at
42.9-79% continence depending on the sling type,
with the long-term durability undetermined [14].
Lastly, the artificial urinary sphincter is currently
the gold standard for the treatment of male SUI.
Although the short-term success rates are excellent
with the artificial urinary sphincter at 82%, this
implantable device has a higher risk of reoperation
rate within 8 years [15]. Critically, the patient has
to be willing and able to work the device on his
own.
LOWER URINARY TRACT SYMPTOMS (LUTS) AND
BENIGN PROSTATIC HYPERPLASIA (BPH)

Lower Urinary Tract Symptoms (LUTS)
describe symptoms related to the lower urinary
tract, including the bladder, prostate, and urethra.
These symptoms are classified into obstructive and
irritative to help identify the cause. Irritative
symptoms include urinary frequency, urgency, urge
incontinence and nocturia. Obstructive symptoms
often include weak urinary flow rate, straining to
urinate, urinary retention, and overflow urinary
incontinence. In men the most common cause of
LUTS is Benign Prostatic Hyperplasia (BPH), which
can have either irritative or obstructive voiding
symptoms.
Pathophysiology
There are many theories to the cause of
LUTS from BPH, but most agree that the hyperplasia of the prostatic cells within the prostatic
urethra is responsible for some of the urinary
symptoms [16]. In particular, obstructive symptoms
are thought to be due to compression of the urethra
caused by hypertrophy of the prostate. As for the
irritative symptoms, it is believed to be due to the
prostate obstructing the bladder outlet with
resultant hypertrophy of the bladder wall muscle.
Clinical presentation
The clinical presentation of BPH is variable,
but most men present with complaints of LUTS.
These men are usually over 50, with concerns
including both obstructive and irritative symptoms
of varying severities. The risk of developing BPH
increases with age and can be high as 70% in men
over the age of 75 [17]. The most commonly reported
symptoms include nocturia, daytime frequency, and
a feeling of incomplete voiding. The development
of symptoms is gradual, over several years, which
may make these symptoms challenging to notice.
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Assessment and diagnosis

Minimally invasive therapy (MIT)

The first step in evaluation is a detailed
history querying the duration and progression of
the patient’s urinary symptoms. Physicians should
also assess the impact of LUTS on the patient’s
quality of life. Both goals can be accomplished
using International Prostate Symptoms Score (IPSS)
questionnaire. Next, a urinalysis is needed to rule
out infection and hematuria. A physical exam should
include a digital rectal exam (DRE) to check the
prostate enlargement, as well as a discussion
regarding prostate cancer screening including blood
PSA testing. Elevated PSA results should prompt a
urology consult. Non-invasive testing including
urinary flow rate and a post-void residual (PVR)
ultrasound scan can be helpful in assessing the
severity. Low flow rates and high PVR values both
increase the suspicion for BPH. In complicated
clinical scenarios where neurogenic bladder dysfunction or overactive bladder may be occurring
concurrently with BPH, a urodynamic evaluation is
helpful. In these cases, seeking a urological
consultation is immensely beneficial for patient
management. BPH is a clinical diagnosis, and the
decision to treat is based on the severity of
symptoms, evidenced by a high PVR volume, UTI,
and extent of negative impact on QOL experienced
by the patient. Accordingly, BPH is mostly a
disease affecting QOL, but it can lead to more
serious medical complications such as urosepsis,
bladder stones, and renal insufficiency due to
chronic outlet obstruction.

MITs have become very popular in the
treatment of BPH because they are outpatient
procedures. MIT is reserved for patients that are
failing medical therapy or considering coming off
medical therapy. These therapies aim to decrease
the amount of prostatic obstruction to the urethra.
Some of the common minimally invasive therapies
include a urethral lift procedure (UroLift) and
steam therapy (Rezum). These are newer technologies with limited long term data, compared to
older MIT such as transurethral needle ablation
(TUNA), which is no longer recommended and
transurethral microwave therapy (TUMT), which
has been shown to have higher reoperations rates
than other options. MITs are outpatient procedures,
requiring no general anesthesia and are associated
with less sexual side effects, such as retrograde
ejaculation, which can be prominent in the surgical
therapies [20]. These advantages make MIT a very
desirable option for a patient suffering from BPH.

Non-surgical treatment
The first line of treatment for LUTS from
BPH is non-surgical therapy. Depending on the
most prominent symptoms, patients may also be
advised to undergo behavioral modifications. For
example, patients with prominent nocturia may be
counseled to limit their fluid intake after dinner to
decrease symptom severity. For medications, alphablockers are the first line therapy and the most
common treatment modality for the management of
BPH [18]. A significant side effect is hypotension,
which can limit its use. Patients unable to take
alpha-blockers or who fail treatment can be started
on 5-alpha reductase inhibitors. Patients on both
these medications for their treatment of BPH are
considered to be on maximal medical therapy.
Newer studies have suggested that Tadalafil may be
helpful in patients with LUTS, with a mechanism
similar to that of alpha-blockers [19]. Patients
considering further intervention will need to be
referred to an urologist.

Surgical therapy
Surgical therapy is reserved for those who
have failed medical therapy, or who are unwilling
to continue medications or use other therapies.
There are several surgical therapies available for
BPH, with the gold standard being TURP. TURP is
now considered size independent, though larger
prostates above 80-100 grams, are often considered
for other procedures. Alternatively, Holmium laser
enucleation of the prostate (HoLEP) is a promising
procedure that can treat any size prostate endoscopically. Other techniques include ablative procedures,
such as the Green Light, Diode laser ablation of the
prostate, and Aquablation which uses high velocity
water jets to ablate prostatic tissue. Another option
is the transurethral incision of the prostate (TUIP),
which is recommended for prostates below 30 grams.
The decision for which type of surgery is discussed
between the urologist and the patient based on
patient characteristics and preference.
OVERACTIVE BLADDER (OAB), URINARY URGE
INCONTINENCE (UUI)

Overactive active bladder (OAB) syndrome
represents an array of symptoms including urinary
urgency, frequency, and urge incontinence (UUI).
UUI is defined as the sudden, involuntary loss of
urine associated with feelings of urgency to void.
The hallmark OAB syndrome is urinary urgency
and may be accompanied by UUI [21]. Men with
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these symptoms should also be evaluated for BPH
since LUTS and OAB often overlap. Urinary tract
infections, prostatitis, and cystitis should be ruled
out with urine cultures before starting treatment for
OAB.
Pathophysiology
The pathophysiology of idiopathic OAB syndrome is poorly understood and currently thought
to be multifactorial [22]. Some neurologic conditions,
such as multiple sclerosis and Parkinson’s disease,
can cause bladder overactivity and be mistaken for
idiopathic OAB syndrome. It is important to rule
out these conditions before initiating treatment for
OAB. Additionally, patients with bladder outlet
obstruction from BPH can also have symptoms that
can be mistaken for OAB and must be ruled out.
Other causes of urinary symptoms that mimic OAB
include bladder cancer, non-infectious cystitis, and
prostatitis. All should be ruled out before beginning
treatment of OAB.
Clinical manifestation
Men with OAB will often describe episodes
of a sudden need to void without much warning,
often struggling to make it to the bathroom before
the initiation of voiding. OAB can be divided into
two separate subtypes – dry and wet. Patients with
dry OAB have severe urgency but denie episodes
of urinary incontinence. Conversely, wet OAB is
urinary urgency commonly associated with incontinence. Wet OAB comprises 33% of OAB cases
[23].
Assessment and diagnosis
Men with OAB will report some degree of
urinary urgency that is affecting their daily life. It
is important first to confirm that the patient is
experiencing UUI, rather than SUI or mixed
incontinence. A detailed history, including duration
and severity of symptoms, is important. Severity
can be assessed by the number of pads used per day
if the patient is using pads. A bladder diary
documenting fluid intake, urine output, and voiding
episodes can be given to the patient to complete
before future office visits and can be helpful for
decision making. OAB symptoms in men over 50
present a challenging situation for the clinician due
to the increased risk of concomitant BPH, and the
large amount of overlapping symptoms between
the two conditions. Patients that have bladder outlet
obstruction from BPH and OAB syndrome should
be evaluated by an urologist.
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Nonsurgical treatment
Management of OAB syndrome begins with
non-surgical intervention. Behavioral modification
is the first step. Patients should be adequately
counseled on avoiding bladder irritants such as
caffeine, alcohol, artificial sweeteners, as well as
preventing dehydration or overhydration. Modifications in behavior are often effective in reducing
the symptoms of OAB and UUI [24]. The role of a
pelvic floor physical therapist in this clinical
situation may be helpful, but it is not as well
established for men as it is in women.
Most experts agree that BPH should be
treated before the initiation of medical therapy for
OAB [25]. Treating BPH first is done to avoid the
risk of causing urinary retention, a side effect of
many OAB treatments. Occasionally, pharmacotherapy for BPH can also lead to symptomatic
relief of OAB. These clinical situations can be
difficult, and a referral to a specialist is warranted.
Men who continue to have isolated OAB
syndrome after behavioral modification, in the
absence of BPH or neurologic bladder dysfunction,
are candidates for pharmacologic therapy. Two main
classes of OAB medications exist – antimuscarinics
and beta-3 agonists. No conclusive evidence supports
the use of one OAB medication over the other,
although each has a different side effect profile
which should be considered when deciding. Bladder
diaries should be obtained before and after the
initiation of medical therapy to judge the effectiveness of the medication. The efficacy of the drug
requires a minimum of 4-6 weeks before alternative
therapies are considered.
Surgical treatment
Men with isolated OAB that have failed
nonsurgical treatment should be referred to an
urologist. Posterior tibial nerve stimulation (PTNS),
an outpatient procedure performed by an urologist,
is offered on a weekly basis for 6 weeks. This is a
minimally invasive form of neuromodulation that
has been proven effective in the treatment of OAB,
working as well as medications but with less side
effects [26].
Other surgical treatments available include
intradetrusor Botox® injections and sacral neuromodulation therapy (Interstim®). Intradetrusor
Botox injections can be performed in the office
without anesthesia while implantation of the Interstim
devices requires a procedure with sedation or general
anesthesia in the operating room setting.
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OVERFLOW URINARY INCONTINENCE AND
DETRUSOR UNDERACTIVITY (DUA)

Detrusor underactivity (DUA) is a cause of
urinary incontinence due to overflow. DUA occurs
due to incomplete emptying of the bladder due to
decreased contractile strength. This can have significant impacts on quality of life, with both
voiding and storage symptoms present. DUA and
overflow incontinence condition is seen more
prevalently in the elderly population, with some
studies showing that 48% of men over the age of
70 are affected by this condition [27]. The presence
of bladder outlet obstructions can further complicate
this condition.
Pathophysiology
The pathophysiology of detrusor underactivity
is poorly understood, in part due to the many
possible causes of this condition, such as myogenic,
neurogenic, or idiopathic. Underactivity may be the
result of poor detrusor muscle function or poor
neurological control with problems possible at any
point in the neurological pathway [28]. It is currently
thought that age, diabetes, and other neurological
risk factors such as stroke or neurodegenerative
disease all confer a high risk for DUA. Current
research is assessing the possibility of urothelial
dysfunctions role in the DUA process [29]. This
work suggests that impaired signaling and sensory
transduction from the urothelium itself may play a
role in DUA.
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method to diagnose detrusor underactivity, with results
showing low pressure and low flow indicative of
underactivity [28, 30, 31].
Treatment
Overall this is a significantly under-researched
condition. These patients should be referred to an
urologist both for testing to confirm the diagnosis,
as well as management. Treatment options attempt
to prevent complications and improve contractile
strength. Currently, there is a lack of any data
showing medications as beneficial. As many of
these patients have concurrent bladder outlet
obstruction, there have been attempts to relieve this
obstruction in hopes of improving DUA symptoms.
This approach has shown poor results, with many
patients having unsatisfactory outcomes after prostate
reducing procedures [32]. Electrical stimulation of
the bladder via an implantable device has also been
a topic of interest for these patients. In the very
limited patients who have undergone this procedure,
there have been significant increases in voided
volume and a reduction in PVR volume [33],
though this may not work well in all patients [34].
Other approaches to treatment include placement
of a suprapubic catheter to drain the bladder, or
urinary diversion to avoid complications.
FEMALE VOIDING DYSFUNCTION
FEMALE STRESS URINARY INCONTINENCE (SUI)

Clinical manifestation

Pathophysiology

There are no specific symptoms associated
with this disorder. The symptoms seen with DUA
mimic those of bladder outlet obstruction and
overactive bladder [30]. Patients may present with
symptoms of storage, such as nocturia, urgency,
and frequency. It is also possible patients may lack
any urge to void at all, and may present with DUA
and overflow incontinence in this manner as well.
Generally speaking, these patients have a weak
stream with incomplete emptying if they can void.
A further complication is added in patients with a
neurological disease which alters sensation.

SUI occurs when urethral resistance is
overcome by increased intra-abdominal pressure,
and should be thought of as “activity related
incontinence”. In female patients, SUI is the result
of poor mucosal coaptation (intrinsic sphincter
deficiency), lack of peri-urethral support structures
(Hammock hypothesis), or a combination of factors
[35]. Risk factors for developing SUI include
pregnancy and childbirth, increasing age, obesity,
previous pelvic surgery, and chronic cough.

Assessment and diagnosis

Women with SUI will complain of urinary
incontinence while coughing, laughing, or sneezing.
Women may also complain of incontinence during
a spectrum of physical activities (e.g., brisk walking to
high impact jumping). Although it does not pose a
medical threat to most patients, SUI can have a
negative impact on a woman’s quality of life [36].

Diagnosis of this condition can be difficult,
as test results often have very similar findings in
detrusor underactivity and bladder outlet obstruction.
Utilizing flow rate and PVR testing is inadequate
for this reason. Urodynamics is the only accepted

Clinical presentation
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Assessment and diagnosis
While obtaining a clinical history, some women
may offer a clear history of SUI and others may
need help determining if they experience SUI, urgency
urinary incontinence, or mixed urinary incontinence (both stress and urgency incontinence).
“What are you doing when you leak?” is an
effective way to start the conversation. History
should include duration of incontinence, severity
(number of pads per day), and degree of bother.
SUI that is not bothersome often does not require
clinical intervention. A limited pelvic exam to
demonstrate leakage while a patient coughs or
bears down can help solidify the diagnosis, but it is
not required for non-surgical treatments.
Non-surgical treatment
SUI can be managed with non-surgical
interventions. Women who perform daily pelvic
floor muscle therapy (PFMT) regimens (e.g. Kegel
exercises) report significant improvement in validated
SUI bother scores and quality of life metrics [37].
If woman interested in following a PFMT regimen
at home, proper Kegel technique should be reviewed
in the office or patients should be referred to a
pelvic floor physical therapist for proper instruction.
While many women may recognize the term
“Kegel exercise,” nearly half of women do not
perform Kegel exercises correctly [38]. In addition
to PFMT, vaginal inserts provide mechanical
support at the level of the urethra and subsequently
reduce the severity of SUI. Although continence
pessaries are to be managed by a specialist, women
can be instructed to use an over the counter product
that is inserted like a tampon (Poise® Impressa®).
These easily accessible products are best for use
during situations when women increase their physical
activity level (e.g. trip to the gym). Non-surgical
management options for SUI are associated with
minimal risk and should be offered to all patients
with bothersome SUI before pursing specialty
referral.
Surgical treatment
Women with SUI who have failed nonsurgical treatment or who do not wish to pursue
non-surgical treatments should be referred to a
specialist. Surgical treatments available include
peri-urethral bulking agents and various types of
urethral slings. Injection of peri-urethral bulking
agents is meant to improve urethral coaptation.
Documented efficacy rates for peri-urethral bulking
agents vary from 22-66%, with only short term
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improvement in SUI [39]. Urethral slings offer
superior success rates with short term success
ranging from 62 to 97% [40]. Urethral slings can
be made of polypropylene mesh, a biologic graft,
or autologous fascia. Urethral slings remain the
gold standard for the surgical management of SUI.
OVERACTIVE BLADDER (OAB)/URGENCY URINARY
INCONTINENCE (UUI)

The hallmark of OAB syndrome is urinary
urgency. OAB is usually accompanied by frequent
urination with or without UUI. Women with OAB
should not have a urinary tract infection or other
obvious lower urinary tract pathology to explain
their urinary urgency.
Pathophysiology
The pathophysiology of idiopathic OAB is
not well understood and the etiology of OAB
symptoms in most women is likely multifactorial.
A number of neurologic conditions can promote
bladder spasms (overactive detrusor muscle), including
multiple sclerosis, Parkinson’s disease, suprasacral
spinal cord injuries, and previous cerebrovascular
accidents. OAB symptoms can also manifest in
patients with mechanical bladder outlet obstruction
(e.g. pelvic organ prolapse), bladder cancer or noninfectious cystitis (e.g. radiation cystitis, painful
bladder syndrome/interstitial cystitis).
Clinical presentation
Women with OAB suffer from a sudden need
to void and “not enough warning time” to get to the
bathroom. They often report frequent urination
during the daytime and nocturia. Approximately
one third of women with OAB syndrome will also
complain of UUI episodes when they cannot get to
the bathroom in time [41]. The prevalence of UUI
is approximately 50% in OAB patients with diabetes
[42].
Assessment and diagnosis
Women with OAB must report some degree
of urinary urgency that is bothersome to them.
Some women may also offer a clear history of UUI
and other women may need help determining if
they experience UUI, SUI, or mixed urinary incontinence. “What are you doing when you leak?” is a
good way to start the conversation. The history
should include duration of symptoms, the severity
of their incontinence (number of pads per day) if
they complain of UUI, and degree of bother.
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Non-surgical treatment
Treatment of women with bothersome OAB
and UUI should start with non-surgical interventions.
The treatment algorithm should always include
behavioral modifications, which may dramatically
improve OAB symptoms and UUI. These women
should be counseled to minimize their intake of
bladder irritants and to avoid dehydration or overhydration. If a patient cannot provide a reliable
fluid intake history, then a 3 day bladder diary is
helpful to identify bladder irritants, capture instances
of fluid mismanagement, and document just how
frequently these women are voiding and having
episodes of UUI [43]. Beyond behavioral modifications, women can participate in PFMT
regimens with or without the guidance of a pelvic
floor physical therapist.
Those who continue to have bothersome
symptoms following behavioral modification are
candidates for pharmacologic therapy. There are
two classes of OAB medications, anti-muscarinics
and beta-3 agonists, with no conclusive evidence
favoring one OAB medication over another.
Common side effects associated with antimuscarinic medications include dry mouth, dry
eyes, and constipation. The most common side effect
associated with a beta-3 agonist is an increase in
blood pressure. Patients should be counseled that a
medication trial of 3-4 weeks is required before
efficacy is determined.
Finally, women who experience suboptimal
efficacy with an OAB medication alone are candidates for percutaneous tibial nerve stimulation
(PTNS) with a pelvic floor specialist. PTNS is
conducted in the office and patients can continue to
use an OAB medication during their treatment course.
Surgical treatment
Women with OAB who have failed nonsurgical treatment should be referred to a urologist.
Surgical treatments available to address OAB and
UUI include bladder Botox® injections and sacral
neuromodulation (Interstim®). Bladder botox injections can be performed in an office setting, while
implantation of the Interstim® device requires a
minimum of sedation in an operating room setting.
INTERSTITIAL CYSTITIS (IC)/BLADDER
HYPERSENSITIVITY

Pathophysiology
While the pathophysiology of interstitial
cystitis (IC) is not well understood, this diagnosis
is often made in patients with chronic bladder pain
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in the absence of other known etiologies. This
disease often coexists with other chronic pain syndromes such as irritable bowel syndrome and
fibromyalgia and is thought to be analogous to
these chronic pain conditions. However, this terminology is a misnomer as often there is no
evidence of inflammation within the bladder, nor is
this disease associated with abnormalities within
the interstices of the bladder. While little is known
about IC and its hypersensitivity symptoms, neurologic
upregulation of pain sensation and increased
activation of bladder sensory neurons seem to play
a significant role in its development [44, 45].
Disruption in the molecular integrity of the glycolsaminoglycan layer of the bladder mucosa which
protects the bladder from certain irritants may
further exacerbate the condition [46, 47].
Clinical presentation
The chief complaints and presenting symptoms
of an IC patient are highly variable and subjective.
However, the most consistent feature that patient’s
present with are increased discomfort with bladder
filling and immediate relief with voiding [47, 48].
Other general concerns consistent with IC and
bladder hypersensitivity include sensations of
pressure, discomfort or spasms of the suprapubic or
urethral regions. Other irritative symptoms such as
frequency, urgency, and nocturia are also common.
Some patients may even be able to identify an
inciting event that may trigger or worsen their
symptoms such as a UTI, consumption of certain
foods, or during the luteal phase of the menstrual
cycle [49].
Assessment and diagnosis
The goal of diagnostic assessment is to
exclude other treatable conditions and identify
characteristic features of IC. Assessment includes a
thorough history taking, physical examination, and
urinalysis. History should be focused on voiding
symptoms and characteristics of the bladder discomforts. Two standardized questionnaires, namely
the IC Symptom and Problem Index and the
Genitourinary Pain Index can be used to assess the
severity of patient symptoms [50, 51]. The physical
exam should include a pelvic examination and a
digital rectal examination to rule out any other
underlying disorders. Urinalysis can be used to rule
out STI, UTI, or hematuria. Symptoms characterized by bladder discomfort upon bladder filling
are a hallmark for IC after all other possible
etiologies have been excluded.
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Non-surgical treatment
Like most conditions, lifestyle modifications
and non-surgical treatment options should be
pursued first. Behavioral modifications include the
application of cold or heat locally over the area of
discomfort and avoidance of any food or activities
that may exacerbate IC symptoms. For IC and hypersensitive bladder, analgesics such as phenazopyridine
can be used as a short-term relief to minimize pain
and maximize function during an episodic flare-up.
For longer-term medications, amitriptyline is often
suggested as the first-line oral medication [52].
Other recommended medications include pentosan
polysulfate sodium or antihistamines such as hydroxyzine or cimetidine [53]. If these oral medications
do not work, other alternative therapies including
bladder hydrodistention, intravesical instillation
with dimethyl sulfoxide, intradetrusor injection of
botulinum toxin and sacral neuromodulation can be
considered. Observational studies assessing the
efficacy of these therapeutic options remain scarce
and among small sample sizes only [54-57]. Larger,
prospective, randomized studies are required to
further investigate the durability and safety of these
treatments.
Surgical treatment
After all else fails, there is an option to pursue
surgery for the amelioration of bladder discomfort
and symptoms secondary to IC or hypersensitivity.
Urinary diversion involves diverting urine from the
bladder into a continent catheterizable urine pouch
or an incontinent urostomy, with the possibility for
removal of the bladder at the same time. As such,
symptomatic relief can potentially be obtained as
bladder filling and distention is no longer possible.
These complex reconstructive surgeries can reliably
relieve hypersensitivity and irritative symptoms,
but pelvic pain may sometimes persist even if a
cystectomy is performed [58, 59].
DYSFUNCTIONAL VOIDING (DV)

Pathophysiology
Dysfunctional voiding (DV) is a disorder
caused by dyssynergic striated sphincteric activity
at the level of striated urethral sphincter-pelvic
floor complex (SUS-PFC). Individuals with this
disorder do not have any association with any
apparent neurological disease or injury. The DV
disorder is considered habitual, as the result of a
child learning the wrong habits to contract the
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SUS-PFC during voiding as opposed to relaxing it.
These habits may form in part due to a response to
urgency, pelvic discomfort, or with inappropriate
toilet training.
Clinical presentation
Patients with DV often present with urinary
incontinence throughout the day. They may also
present with LUTS such as frequency, urgency,
nocturia and nocturnal enuresis [60]. Storage symptoms are the most common presenting symptom
and may sometimes be the only symptom [61].
Assessment and diagnosis
The American Urological Association Symptom
Score (AUASS) can be used to assess the severity
of a patient’s DV, with authors deriving a cutoff of
6 for girls and 9 for boys to diagnose DV. Other
authors have also created different scoring symptoms,
namely the “wetting and functional voiding disorder”
scoring system by Akbal et al. and 14-item Likert
scale questionnaire by Afshar et al. as aids to
diagnose patients with DV [62, 63]. Besides this,
uroflow and urodynamics studies are also essential
to diagnose DV. Repeated demonstration of a
staccato, interrupted pattern on uroflow is classic
for DV as urinary sphincters do not relax entirely
during voiding. The definitive test to diagnose DV
is visualizing bladder outlet obstruction secondary
to dyssynergic external sphincteric activity on urodynamics testing [64].
Non-surgical treatment
Lifestyle modifications for DV include hypnosis, bladder retraining, and biofeedback to the
pelvic floor with conservative urotherapy. All have
the primary goal of enabling the patient to relax the
bladder outlet during voiding. Anticholinergic
medications such as α-adrenergic blockers may
also serve to relax the bladder neck. In certain
situations, some patients may even benefit from
sphincteric injection with botulinum toxin [65]. In
refractory cases of DV, sacral neuromodulation
with the Interstim device or percutaneous tibial
nerve stimulation has proved to be a safe, durable
and efficacious method in treating DV [66-68].
BLADDER NECK DYSFUNCTION (BND)

Pathophysiology
Primary bladder neck dysfunction (BND)
refers to a functional impedance of urinary flow at
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the level of the bladder neck. BND, however,
develops when the bladder neck hypertrophies, becomes less elastic and increasingly more obstructive,
which impedes urine flow. It is hypothesized that
there is a neurological component linked to this
disorder as studies have shown a relative increase
in the density of neuropeptide Y immunoreactive
nerves and exaggeration of the sympathetic nervous
system in the bladder neck [69, 70]. Additionally,
others have also noted the aberrant orientation of
detrusor and bladder neck muscle fibers resulting in
the narrowing of the bladder neck [71].
Clinical presentation
Patients with BND often present with a combination of symptoms, with the most common
being hesitancy, pelvic discomfort, frequency, urgency,
hesitancy and sense of incomplete emptying or
impaired stream. Occasionally, patients may have a
history of constipation or previous UTI or encopresis [72].
Assessment and diagnosis
Urodynamic studies are often required to
make the definitive diagnosis of BND. On video
urodynamics, patients present with inadequate or
delayed bladder neck funneling during voiding,
quiet pelvic floor throughout voiding, diminished
uroflow despite adequate detrusor contraction and
prolonged opening time [73, 74]. Additionally,
electromyography (EMG) can be done together
with the video urodynamics to show a prolonged
pelvic floor EMG lag time (> 6 seconds) to reinforce
the diagnosis further [75]. If ultrasound studies are
obtained, there may be evidence of bladder wall
thickening and elevated post-void residual volume.
Overall, evidence of diminished urine flow rates in
the presence of high voiding detrusor pressures is
the hallmarks of obstruction.
Non-surgical treatment
Biofeedback therapy with pelvic floor
manipulations, timed voiding, and anticholinergic
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medications do not seem to be effective in treating
BND as the autonomic nervous system primarily
controls the bladder neck. To date, α-adrenergic
antagonists have remained the first-line medical
therapy for BND [76]. Tamsulosin seems to be the
most tolerable α-blocker with similar efficacy
among children.
Surgical treatment
Patients with delayed treatment for BND may
develop worsening detrusor dysfunction such that
they become resistant to medical therapies such as
α-blocker. In such cases, surgical management,
such as the transurethral incision of the prostate or
bladder neck, may be warranted [77, 78]. Due
to the more invasive fashion of these treatment
alternatives, there is an increased risk of sexual
dysfunction such as retrograde ejaculation.
CONCLUSION

Voiding dysfunction is a common complaint
in both men and women, and although it can be
difficult for patients to talk about due to the
intimate anatomy and nature of this condition, it
nonetheless has major quality of life implications
and carries a great cost to society. As the workforce
shortage in urology grows, it is vital that other
practitioners, namely primary care, step in to provide
the proper care to these patients. Accordingly, these
clinicians should be able to recognize the varying
conditions associated with voiding dysfunction,
evaluate and treat these patients with first-line
therapies, and be able to identify which patients
require a referral to an urologist.
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O scădere a forţei de muncă a urologilor este prevăzută în Statele Unite în
decadele viitoare. În lumina acestor date managementul unor afecţiuni urologice
va fi preluat de către medici din alte specialităţi. Medicii de familie sunt prima
linie de intervenţie şi cel mai probabil ei vor trata aceste afecţiuni. Una dintre cele
mai frecvente afecţiuni urologice este pieredera involuntară de urină. Incidenţa
acesteia creşte odată cu vârsta, considerându-se că mai mult de 50% dintre
pacienţii în vârstă suferă de această afecţiune. În ciuda prevalenţei înalte şi al
impactului negativ asupra calităţii vieţii puţini pacienţi doresc să se trateze
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întrucât puţini recunosc simptomele. Scopul acestui review este de a prezenta
evaluarea şi abordarea terapeutică a incontinenţei urinare la pacienţii de gen
feminin şi masculin.
Correspondence to: Costas D. Lallas, MD, FACS, 1025 Walnut St, Ste 1100,
Philadelphia, PA 19107, Telephone: 215-955-1416
E-mail: Costas.Lallas@jefferson.edu
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